Is There Any Difference in PBPC Mobilization Between Cyclophosphamide Plus G-CSF and G-CSF Alone in Patients with Non-Hodgkin's Lymphoma?

References

• Gratwohl A, Passweg J, Baldomero H, Hermans J. Blood and marrow transplantation activity in Europe 1997. Bone Marrow Transplant 1999; 24: 231–245
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J Y, Harousseau J L, Coiffier B, Biron P, Mandelli F, Chauvin F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard P, Reyes F. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: update results of the prospective study LNH87–2. J Clin Oncol 1997; 3: 1131–1137
   Google Scholar
• To L B, Roberts M M, Haylock D N, Dyson P G, Branford A L, Thorp D, Ho J QK, Dart G W, Horvath N, Davy M LJ, Olweny C LM, Abdi E, Juttner C A. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogenic bone marrow transplant. Bone Marrow Transplant 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• Henon P R, Liang H, Beck-Wirth G, Eisenmann J C, Lepers M, Wunder E, Kandel G. Comparison of haematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285–291
   PubMed Web of Science ®Google Scholar
• Beyer J, Schwella N, Zingsem J, Strohscheer Schwaner I, Oettle H, Serke S, Huhn D, Siegert W. Haematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328–1335
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch D C, Greger P, Goldstone A H, Boogaerts M A, Ferrant A, Demuynck H MS, Link H, Zander A, Barge A, Borkett K. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• Smith T J, Hillner B E, Schmitz N, Linch D C, Goldstone A H, Booaerts M A, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder M H. Economic analysis of a randomized clinical trials to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5–10
   PubMed Web of Science ®Google Scholar
• Ross A A, Cooper B W, Lazarus H M, Mackay W, Moss T J, Ciobanu N, Tallman M S, Kennedy M J, Davidson N E, Sweet D, Wimer C, Akard L, Jansen J, Copelan E, Meagher R C, Herzigh R H, Klumpp T R, Kahn D G, Warner N E. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605–10
   PubMed Web of Science ®Google Scholar
• Langlands K, Craig J IO, Parker A C, Anthony R S. Molecular determination of minimal residual disease in peripheral blood stem cell harvests. Bone Marrow Transplant 1990; 5: 64–65
   PubMed Web of Science ®Google Scholar
• Serke Sauberlich S., Huhn S. D. Multiparameter flow cytometrical quantitation of circulating haemopoictic progenitors cells by in vitro colony-assay. Br J Haematol 1991; 77: 453–459
   PubMedGoogle Scholar
• Zimmerman T M, Lee W J, Bender J G, Mich R, Williams S F. Quantitative CD 34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 1905; 9: 439–444
   Google Scholar
• Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern A C, Lansdorp M, Bonadonna G, Gianni M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400–409
   PubMed Web of Science ®Google Scholar
• Haas R, Möhle R, Frühauf S, Goldshmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cell in malignant lymphoma. Blood 1994; 12: 3787–3794
   Google Scholar
• Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buckner C D. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555
   PubMed Web of Science ®Google Scholar
• Kiss J E, Rybka W B, Winkelstein A, deMagalhaes-Silverman M, Lister J, D'Andrea P, Ball E D. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303–310
   PubMed Web of Science ®Google Scholar
• Weaver C H, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 10: 3961–3969
   Google Scholar
• Dazzi C, Cariello A, Rosti G, Monti G, Baioni M, Zarnetta L, Ferrari E, Scarpi E, Fiorentini G, Marangolo M. There is a role for the number of PBPC reinfused in breast cancer patients receiving high doses of thiotepa and melphalan. Relationship between CD34+ cells subsets and engraftment kinetics. Haematol 2000; 85: 396–402
   PubMed Web of Science ®Google Scholar
• To L B, Dyson P G, Juttner C A. Cell dose effect in circulating stem-cell autografting. Lancet 1986; ii: 404–405
   Google Scholar
• Jones R J, Celano P, Sharkis S J, Sensenbrenner L L. Two phases of engraftment established by serial bone marrow transplantation in mice. Blood 1989; 73: 397–401
   PubMed Web of Science ®Google Scholar
• Pecora A, Preti R A, Gleim W G, Jennis A, Zahos K, Cantwell S, Doria L, Isaacs R, Gillio A P, Michelis M A, Brochstein J A. CD34+CD33-cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998; 16: 2093–2104
   PubMed Web of Science ®Google Scholar
• Möhle R, Pförsich M, Fruehauf S, Witt B, Krämer A, Haas R. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant 1994; 14: 827–832
   PubMed Web of Science ®Google Scholar
• Cesana C, Carlo-Stella C, Regazzi E, Garau D, Sammarelli G, Caramatti C, Tabilio A, Mangoni L, Rizzoli V. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Bone Marrow Transplant 1998; 21: 561–568
   PubMed Web of Science ®Google Scholar
• Kröger N, Zeller W, Fehse N, Hassan H T, Krüger W, Gutensohn K, Lölliger C, Zander A R. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998; 102: 1101–1106
   PubMed Web of Science ®Google Scholar
• Zeller W, Gutensohn K, Stockschläder M, Dierlamm J, Kroger N, Koehne G, Hummel K, Kabisch H, Weh H J, Kühnl P, Hossfeld D K, Zander A R. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 1996; 17: 709–713
   PubMed Web of Science ®Google Scholar
• Webb I J, Eickoff C E, Elias A D, Ayash L J, Wheeler C A, Schwartz G N, Demetri G D, Anderson K C. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for timing and yield of hematopoietic progenitor cell collections. Transfusion 1996; 36: 160–167
   PubMed Web of Science ®Google Scholar
• Bender J G, Lum L, Unverzagt K L, Lee W, Van Epps D, George S, Coon J, Ghalie R, McLeod B, Kaizer H, Williams S F. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 1994; 13: 479–485
   PubMed Web of Science ®Google Scholar
• Schwella N, Rick O, Meyer O, Löffel J, Schleicher J, Serke S, Huhn D, Ries H. Mobilization of peripheral blood progenitor cells by disease-specific chemotherapy in patients with soft tissue sarcoma. Bone Marrow Transplant 1998; 21: 863–868
   PubMed Web of Science ®Google Scholar
• Dazzi C, Cariello A, Rosti G, Monti G, Sebastiani L, Argnani M, Nicoletti P, Tienghi A, Leoni M, Fiorentini G, Turci D, Giovanis P, De Giorgi U, Marangolo M. Peripheral blood progenitor cell mobilization in heavily pretreated patients with germ cell tumors: a report of 34 cases. Bone Marrow Transplant 1999; 23: 529–532
   PubMed Web of Science ®Google Scholar
• Lane T A, Ho A D, Bashey A, Peterson S, Young D, Lato P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage and granulocyte-colony-stimulating factors. Transfusion 1999; 39: 39–47
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Stiff P, Gordon M S, McNiece I, Ho A D, Costa J J, Broun E R, Bayer R A, Wyres M, Hill J, Jelaca-Maxwell K, Nichols C R, Brown S L, Nimer D, Gabrilove J. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients: results of a phase I/II trial. Blood 1997; 9: 3136–3147
   Google Scholar